Terminated NA INTERVENTIONAL NCT00226200

Soluble CD23 Expression in Asthma Patients Treated With OMA

Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab

Sponsor: Novartis Pharmaceuticals

Conditions Asthma

Interventions Omalizumab

Updated 5 times since 2017 Last updated: Nov 26, 2008 Started: Nov 30, 2004 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Completed

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Asthma trials with similar outcome

Browse all Asthma trials

This NA trial investigates Asthma and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals
University of Mississippi Medical Center

Data source: University of Mississippi Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jackson, United States